Clinical Trial

Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas

Study acronym: NAPACA
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-01; most recent amendment 2025-08-24.
Trial Details
NCT Number NCT04917757
Lead Sponsor Wuerzburg University Hospital
Collaborators: European Network for the Study of Adrenal Tumors
Conditions Adrenal Incidentaloma
Enrollment 3,656 participants
Start Date 2015-01-01
Primary Completion 2019-08-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-05